Thomas L. Avery

Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213

Gaston K. Rivera, Thomas L. Avery, DeWayne Roberts · European Journal of Cancer (1965) · 1975 · 84 citations

Life Sciences, Biochemistry, Molecular Biology +2

Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice.

Thomas L. Avery, Jerold E. Rehg, W C Lumm et al. · PubMed · 1989 · 75 citations

Medicine, Molecular Biology, Pharmacology +6

Antitumor and antiviral activity of synthetic .alpha.- and .beta.-ribonucleosides of certain substituted pyrimido[5,4-d]pyrimidines: a new synthetic strategy for exocyclic aminonucleosides

Yogesh S. Sanghvi, Steven B. Larson, Steven S. Matsumoto et al. · Journal of Medicinal Chemistry · 1989 · 72 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15

Combined VM-26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia

Gaston K. Rivera, Rhomes J. A. Aur, Gary V. Dahl et al. · Cancer · 1980 · 64 citations

Medicine, Hematology, Pharmacotherapy +12

VM-26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia

Gaston K. Rivera, Gary V. Dahl, W. Paul Bowman et al. · Cancer · 1980 · 57 citations · Full text

Medicine, Oncology, Pharmacology +17